DrugPatentWatch Database Preview
Drugs in Development Information for QGC001
» See Plans and Pricing
What is the drug development status for QGC001?
QGC001 is an investigational drug.
There have been 8 clinical trials for QGC001.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2020.
The most common disease conditions in clinical trials are Hypertension, Ventricular Dysfunction, Left, and Ventricular Dysfunction. The leading clinical trial sponsors are Quantum Genomics SA, Quotient Sciences, and [disabled in preview].
There are three US patents protecting this investigational drug and forty-seven international patents.
Summary for QGC001
| US Patents | 3 |
| International Patents | 47 |
| US Patent Applications | 2 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2020-03-01) |
| Vendors | 7 |
Recent Clinical Trials for QGC001
| Title | Sponsor | Phase |
|---|---|---|
| Firibastat in Treatment-resistant Hypertension | Quantum Genomics SA | Phase 3 |
| Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations | Quotient Sciences | Phase 1 |
| Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations | Quantum Genomics SA | Phase 1 |
Clinical Trial Summary for QGC001
Top disease conditions for QGC001
Top clinical trial sponsors for QGC001
US Patents for QGC001
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| QGC001 | Start Trial | Derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfonates) and compositions comprising the same | Institute National de la Sante et de la Recherche Medicale (Inserm) (Paris Cedex, FR) | Start Trial |
| QGC001 | Start Trial | Method for the preparation of (3S, 3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) | QUANTUM GENOMICS (Paris, FR) | Start Trial |
| QGC001 | Start Trial | Method for the preparation of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) | QUANTUM GENOMICS (Massy, FR) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for QGC001
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| QGC001 | Austria | 455097 | 2023-08-06 | Start Trial |
| QGC001 | Canada | 2533432 | 2023-08-06 | Start Trial |
| QGC001 | Cyprus | 1109950 | 2023-08-06 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
